- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03721809
Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis (SAMOKINE)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patient hospitalized in intensive care for macrophage activation syndrome secondary to sepsis / bacterial septic shock with a strong clinical probability score (defined by a HScore> 80% cf appendix 4) (experimental population) or Patient hospitalized in intensive care for sepsis or septic shock (control population)
- Age ≥ 18 years
- Person affiliated with a social security scheme or beneficiary of such a scheme
- Trusted person or informed patient who has signed the consent to participate in the research. (If the patient is unable to sign his / her consent (emergencies) the consent will be signed by the person of trust, and consent to further study will be requested from the patient).
- Effective contraception in women of childbearing potential (negative pregnancy test). For postmenopausal women, a confirmation diagnosis should be obtained (amenorrhea for at least 12 months before the inclusion visit).
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Person deprived of liberty by an administrative or judicial decision
- Protected major subject, under tutorship or curatorship
- Patient participating in another interventional clinical trial with the same primary objective
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: macrophage activation syndrome secondary to bacterial sepsis
Patients hospitalized in medical intensive care for macrophage activation syndrome secondary to bacterial sepsis
|
There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube. On D1, a 2.5ml PAXgene tube will also be taken for each patient. |
Other: bacterial sepsis/septic shock
Patients hospitalized in medical intensive care for sepsis / septic shock
|
There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube. On D1, a 2.5ml PAXgene tube will also be taken for each patient. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
quantitative measurement of plasma IL-1β in MAS patients secondary to septic sepsis / bacterial septic shock in comparison with a control population of sepsis /septic shock.
Time Frame: performed on day 1
|
measured by the luminex method
|
performed on day 1
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017/185/HP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macrophage Activation Syndrome
-
Gunnar LachmannCompletedHemophagocytic Lymphohistiocytosis (HLH) | Macrophage Activation Syndrome (MAS) | Hemophagocytic Syndromes
-
Beijing Friendship HospitalNot yet recruitingMacrophage Activation Syndrome
-
University of Alabama at BirminghamActive, not recruitingMacrophage Activation SyndromeUnited States
-
Peking University People's HospitalUnknownMacrophage Activation SyndromeChina
-
Hellenic Institute for the Study of SepsisCompletedSepsis | Macrophage Activation SyndromeGreece
-
Amrita Institute of Medical Sciences & Research...UnknownLymphohistiocytosis, Hemophagocytic | Macrophage Activation SyndromeIndia
-
National Cancer Institute (NCI)Active, not recruitingMacrophage Activation Syndrome | Primary Hemophagocytic LymphohistiocytosisUnited States
-
National Institute of Allergy and Infectious Diseases...RecruitingLymphohistiocytosis, Hemophagocytic | Macrophage Activation Syndrome | Secondary Hemophagocytic Lymphohistiocytosis | Hyperinflammatory SyndromesUnited States
-
FSD Pharma, Inc.TerminatedMast Cell Activation Syndrome | Mast Cell Activation Disorder IdiopathicCanada, United States
-
Oxford University Clinical Research Unit, VietnamHospital for Tropical Diseases, Ho Chi Minh City, VietnamRecruitingCytokine Storm | Dengue | Severe Dengue | Macrophage Activation Syndrome | Anakinra | Dengue With Warning Signs | Anti-inflammatory Agents | Hyperinflammatory Syndrome | Immuno-modulationVietnam
Clinical Trials on Blood samples
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Centre Georges Francois LeclercCompleted
-
Centre Hospitalier Universitaire DijonCompletedPrimary Immune Thrombocytopenia (ITP)France
-
Institut BergoniéUnknown
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownPaediatric MalignanciesFrance
-
Centre Hospitalier Universitaire de NīmesCompletedHenoch Schönlein PurpuraFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Assistance Publique Hopitaux De MarseilleRecruitingPlastic SurgeriesFrance
-
University Hospital, BordeauxRecruitingSystemic Sclerosis | SclerodermaFrance
-
Centre Hospitalier Universitaire, AmiensCompleted